Literature DB >> 34978026

Inhibition of Microglial NLRP3 with MCC950 Attenuates Microglial Morphology and NLRP3/Caspase-1/IL-1β Signaling In Stress-induced Mice.

Qing Liu1, Man-Man Zhang1, Min-Xia Guo2, Qiu-Ping Zhang3, Na-Zhi Li2, Jie Cheng1, Shi-Le Wang1, Guang-Hui Xu4, Cheng-Fu Li3, Ji-Xiao Zhu5, Li-Tao Yi6,7,8.   

Abstract

Major depressive disorder is characterized by the deficiencies of monoamine neurotransmitters, neurotrophic factors and persistent neuroinflammation. Microglial activation has been associated with neuroinflammation-related mental diseases, accompanied by NLR family pyrin domain containing 3 (NLRP3) inflammasome. Here, we investigated the effect of NLRP3 inhibition by its small molecular inhibitor MCC950 on inflammatory activity and depressive-like mice induced by chronic unpredictable mild stress (CUMS), followed by the behavioral tests including sucrose preference test and forced swimming test. NLRP3/caspase-1/IL-1β signaling and microglial morphology in the prefrontal cortex were measured. The results showed that CUMS caused a decrease in sucrose preference and an increase in immobility time, which were reversed by NLRP3 inhibitor MCC950. In addition, NLRP3 inhibition decreased the number of microglia and changed the activated state of microglia to a resting state by morphology 3D reconstruction. Moreover, NLRP3 inhibition inactivated NLRP3/caspase-1/IL-1β signaling in the prefrontal cortex. The results from immunofluorescence demonstrated that NLRP3 and IL-1β expression was decreased in microglia in response to MCC950 treatment. Accordingly, proinflammatory cytokines were also decreased by NLRP3 inhibition. In conclusion, this study demonstrates that microglial NLRP3 inhibition prevents stress-induced neuroinflammation in the prefrontal cortex and suggests that microglial NLRP3 could be one of the potential therapeutic targets for depression treatment.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Depression; IL-1β; Microglia; NLRP3; Neuroinflammation

Year:  2022        PMID: 34978026     DOI: 10.1007/s11481-021-10037-0

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  2 in total

1.  Serogrouping and auxotyping for epidemiological study of beta-lactamase-producing Neisseria gonorrhoeae strains isolated in Sweden.

Authors:  S Bygdeman; I Kallings; D Danielsson
Journal:  Acta Derm Venereol       Date:  1981       Impact factor: 4.437

Review 2.  NLRP3 Inflammasome in Neurological Diseases, from Functions to Therapies.

Authors:  Limin Song; Lei Pei; Shanglong Yao; Yan Wu; You Shang
Journal:  Front Cell Neurosci       Date:  2017-03-09       Impact factor: 5.505

  2 in total
  2 in total

1.  S-Ketamine Pretreatment Alleviates Anxiety-Like Behaviors and Mechanical Allodynia and Blocks the Pro-inflammatory Response in Striatum and Periaqueductal Gray From a Post-traumatic Stress Disorder Model.

Authors:  Shuai Yang; Ke Xu; Xuan Xu; Jixiang Zhu; Yinan Jin; Qi Liu; Rui Xu; Xiaoping Gu; Yue Liu; Yulin Huang; Zhengliang Ma
Journal:  Front Behav Neurosci       Date:  2022-04-14       Impact factor: 3.617

Review 2.  Involvement of inflammatory responses in the brain to the onset of major depressive disorder due to stress exposure.

Authors:  Shingo Miyata; Yugo Ishino; Shoko Shimizu; Masaya Tohyama
Journal:  Front Aging Neurosci       Date:  2022-07-22       Impact factor: 5.702

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.